Surgery Partners

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Surgery Partners reports robust Q4 earnings, eyes growth in cardiac care

Surgery Partners' strong financial performance, driven by strategic initiatives and revenue growth, positions the company for continued success. While facing challenges in adoption rates and reimbursement, the company's focus on outpatient care and higher acuity service lines presents growth opportunities. With a proactive approach to recruitment and expansion, Surgery Partners is poised for a positive trajectory in 2023.

Surgery Partners (SGRY) posts robust Q1 results, eyes strategic growth

Surgery Partners (SGRY) delivered strong financial performance, operational efficiency, and strategic growth initiatives in Q1 2023.
Despite challenges from revenue timing and minimal earnings impact in the short term, the company's disciplined approach and focus on partnerships and acquisitions offer promising opportunities.
With a raised adjusted EBITDA outlook, a commitment to excellence, and a clear growth strategy, Surgery Partners is well-positioned for continued success and value creation.

Surgery Partners exceeds Q2 expectations, eyes strategic growth opportunities

Surgery Partners delivered strong financial performance in Q2 2023, surpassing expectations and demonstrating resilience in surgical case growth.
Despite challenges in anesthesia coverage and subsidies, the company remains optimistic about its growth prospects and is focused on operational efficiencies.
Strategic investments in orthopedics and cardiology, along with a commitment to high-quality care, underscore Surgery Partners' long-term growth potential.

Surgery Partners beats Q3 targets, eyes mid-teens growth in 2024

Surgery Partners exceeded Q3 expectations, showcasing strong performance and strategic initiatives. While facing challenges from portfolio adjustments and regulatory proposals, the company is well-positioned for continued growth through acquisitions and focus on high acuity cases.

Surgery Partners (SGRY) reports robust 2023 results and eyes strategic growth in 2024

Surgery Partners (SGRY) delivered strong financial performance in 2023, with a positive outlook for 2024. The company's focus on margin expansion, growth in higher acuity procedures, and strategic acquisitions positions it well for continued success. Challenges include cash flow uncertainties and the impact of unique comp dynamics on case growth.

Surgery Partners (SGRY) reports robust Q1 earnings and eyes strategic acquisitions for continued growth

Surgery Partners (SGRY) delivered strong financial results in Q1 2024, showcasing solid revenue growth and margin expansion. The company's strategic focus on acquisitions, margin improvement initiatives, and effective cost management underpin its optimistic outlook for sustained growth and cash flow generation.

Surgery Partners (SGRY) posts impressive Q2 results, raises full-year outlook

Surgery Partners (SGRY) delivered strong financial performance in Q2 2024, driven by revenue growth, enhanced margins, and strategic acquisitions. Despite facing leverage challenges, the company's focus on specialty physician recruitment and operational efficiency presents opportunities for sustained growth and profitability.

Surgery Partners posts strong Q3 results amidst Hurricane challenges

Surgery Partners demonstrated robust financial performance in Q3 2024, marked by revenue growth, margin expansion, and strategic acquisitions.
While facing challenges from Hurricane Helene, the company's focus on recruitment and growth in key specialties positions it well for future success.
With a strong outlook for the full year and a focus on high-growth markets and specialties, Surgery Partners shows resilience and strategic foresight.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BRENTWOOD, Tenn., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2021 results after market close on Tuesday, November 2, 2021, to be followed by a conference call at 5:00 p.m. (Eastern Time).

Surgery Partners, Inc. Announces Third Quarter 2021 Earnings Release Date and Conference Call Details

Agiliti Inc

HealthEquity

ModivCare

Progyny

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most.

5 Medical Services Stocks Countering Industry Headwinds

Surgery Partners (SGRY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 26.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Surgery Partners (SGRY)

Surgery Partners, Inc. (SGRY) CEO Eric Evans on Q2 2021 Results - Earnings Call Transcript

Surgery Partners (SGRY) delivered earnings and revenue surprises of 100.00% and -0.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Reports Break-Even Earnings for Q2

Shares of Surgery Partners (NASDAQ:SGRY) fell 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.00, which beat the estimate of ($0.20).

Surgery Partners: Q2 Earnings Insights

BRENTWOOD, Tenn., July 09, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2021 results before the market opens on Wednesday, August 4, 2021, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Second Quarter 2021 Earnings Release Date and Conference Call Details

Apollo Medical Hlds

Fulgent Genetics

HCA Healthcare

Joint

Labcorp Holdings Inc

Tenet Healthcare

These seven healthcare stocks are in a good position to take off as baby boomers continue to age into retirement. The post 7 Healthcare Stocks to Buy for Changing Demographics appeared first on InvestorPlace.

7 Healthcare Stocks to Buy for Changing Demographics

ORANGE, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) and UCI Health have announced a new strategic partnership that marks an expansion of community access to outpatient surgical facilities for nearly 4 million residents throughout Orange County, western Riverside County and southern California.

Surgery Partners, Inc. and UCI Health Announce New Strategic Partnership

Surgery Partners, Inc. (SGRY) CEO Eric Evans on Q1 2021 Results - Earnings Call Transcript

Shares of Surgery Partners (NASDAQ:SGRY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 11.76% over the past year to ($0.30), which beat the estimate of ($0.37).

Surgery Partners: Q1 Earnings Insights

BRENTWOOD, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the first quarter ended March 31, 2021.

Surgery Partners, Inc. Announces First Quarter 2021 Results; Completes Refinancing Transactions

Surgery Partners (NASDAQ:SGRY) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to Surgery Partners's Q1 earnings report.

Surgery Partners Earnings Preview

BRENTWOOD, Tenn., April 20, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced its intent to raise incremental term loans, convert Series A Preferred Stock into Company Common Stock and provided a preliminary financial update on first quarter 2021 results.

Surgery Partners, Inc. Announces Term Loan Refinancing and Conversion of Preferred Stock; Provides Preliminary First Quarter 2021 Financial Performance Update

BRENTWOOD, Tenn., April 06, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2021 results before the market opens on Wednesday, May 5, 2021, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces First Quarter 2021 Earnings Release Date and Conference Call Details

Surgery Partners, Inc. (SGRY) CEO Eric Evans on Q4 2020 Results - Earnings Call Transcript

Surgery Partners (NASDAQ:SGRY) announces its next round of earnings this Wednesday, March 10. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

Earnings Preview: Surgery Partners

BRENTWOOD, Tenn., March 01, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced that Dr. Patricia A. Maryland has been appointed to serve as an independent director on its Board of Directors. Dr. Maryland's appointment, which is effective immediately, will increase the size of Surgery Partners' Board to nine members.

Surgery Partners, Inc. Names Patricia A. Maryland, Dr to Board of Directors

BRENTWOOD, Tenn., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2020 results before the market opens on Wednesday, March 10, 2021, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Surgery Partners, Inc. Announces Fourth Quarter 2020 Earnings Release Date and Conference Call Details

BRENTWOOD, Tenn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (Nasdaq: SGRY) (“Surgery Partners”) today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $30.25 per share. Gross proceeds to Surgery Partners from the offering are expected to be approximately $226.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Surgery Partners. In addition, Surgery Partners has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock, at the public offering price less underwriting discounts and commissions. All of the shares in the offering are being sold by Surgery Partners. The offering is expected to close on or about February 1, 2021, subject to customary closing conditions.

Surgery Partners, Inc. Announces Pricing of $226.9 Million Public Offering of Common Stock

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

BRENTWOOD, Tenn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Members of management of Surgery Partners, Inc. (the “Company”) will be meeting with investors as part of the 2021 J.P. Morgan Healthcare Conference the week of January 11th, 2021, including a presentation on Monday, January 11, 2021 at 2:50 p.m. (Eastern Time). Based on results through November 2020, the Company is now providing full year 2020 revenue guidance of approximately $1.86 billion and reaffirming its previous full-year 2020 Adjusted EBITDA guidance range of $250 to $260 million. Consistent with previous management statements, the Company projects that in 2021, it will re-establish the multi-year double-digit Adjusted growth trajectory and profit levels originally targeted based on a pre-COVID baseline. Correspondingly, 2021 Adjusted EBITDA is projected to be approximately $315 million. This information is included in a Corporate Presentation that may be used for these meetings. The Corporate Presentation is available on the Company's website at ir.surgerypartners.com/events-and-presentations/presentations.

Surgery Partners, Inc. Reaffirms 2020 Adjusted EBITDA Guidance and Provides 2021 Initial Adjusted EBITDA Outlook

Surgery Partners runs surgical hospitals and ambulatory surgery centres in partnership with physicians, handling the non-specialist side of the business. The company's share price hit a low of $4.3 in March on pandemic headwinds, but has surged back to trade at $28.

News for Surgery Partners Stock (SGRY)